Reaxys® Medicinal Chemistry Provided as Part of Elsevier’s Suite of Life Science Solutions Delivers High Quality Content to Improve Drug Discovery and Development
AMSTERDAM, February 4, 2013 /PRNewswire/ –
Comprehensive, referenced and well-structured data allows users to increase
speed and accuracy of decision making in the drug development process
Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, today announced the launch of Reaxys
Medicinal Chemistry. It offers medicinal chemists access to comprehensive, referenced and
well-structured data to enhance the compound selection process across discovery and
pre-clinical stages in drug research and development. Reaxys Medicinal Chemistry will
significantly improve the efficiency and productivity of researchers engaged in the
process of designing compounds and optimizing their compatibility with one or more targets
in order to successfully treat a disease.
Dr. Juergen Swienty-Busch, Product Lead for the Reaxys suite at Elsevier, said, “The
greatest challenge of medicinal chemistry is to reduce the number of drug candidates that
fail in late stages, significantly increasing the cost of bringing a drug to market. The
well-known mantra ‘fail early, fail cheap’ is now central to the drug discovery process,
with much of the responsibility borne by medicinal chemists.”
Medicinal chemists develop strategies to find new drugs and to improve not only the
efficacy of compounds but also selectivity, ADME properties and safety end-points. To
support these strategies, medicinal chemists need to have access to up-to-date, well
organized and high-quality experimental data on druggable targets, pharmacological
effects, biological data points, and ADME properties associated with chemical compounds.
Reaxys Medicinal Chemistry sources its data from a vast repository of peer-reviewed
journal articles, patents and regulatory information, encompassing millions of compounds
and associated biological data linked to thousands of druggable proteins. It brings this
information together into a single, easily searchable solution that gives pharmaceutical
companies access to comparative data.
Reaxys Medicinal Chemistry can be used in conjunction with Elsevier’s suite of life
science products; including Reaxys, the leading chemistry discovery engine, and
PharmaPendium, which focuses on regulatory approvals and drug safety. This solution
effectively brings together lead identification, confirmation and drug repurposing.
Reaxys(R) is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys(R) combines reaction and substance data in
organic, organometallic, inorganic and physical chemistry with synthesis planning.
Researchers can get the information they need in a single overview, from source
publications carefully selected for their importance and relevance to research chemists.
Elsevier continues to engage with the chemistry community to ensure that Reaxys(R)
continues to reflect how chemists think and work. For more information please visit
Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA
and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], ClinicalKey
[http://www.clinicalkey.com ] and Mosby’s Nursing Suite [http://www.confidenceconnected.com
], which enhance the productivity of science and health professionals, and the SciVal
suite [http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which
help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading provider of professional information
solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact Harald Boersma Director, Corporate Relations Elsevier +31-20-485-27-36 email@example.com